News | February 25, 2026
Lupin launches generic Brivaracetam oral solution in US to treat epilepsy
Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB
Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
Meenal brings in more than 16 years of international experience across Europe, Asia and the Middle East
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
Subscribe To Our Newsletter & Stay Updated
